Neuroscience Symposium Event Schedule
Thursday, October 31st, 2024

9:00-3:35 Check-In / Walk-In Registration

9:00-10:00 Breakfast Available for All Registrants and Guest Speakers and Chat with Keynote Speaker: Bin Xu, PhD
(for students, postdoctoral fellows, and medical students/residents)

10:00-10:15 Opening Remarks: Tuan Tran, PhD, ECCSfN Interim President

10:15-10:45 Podium Talks (5-10 min each, 3 min questions)

10:45-11:00 Break

11:00-11:55 Keynote Address: Dr. Bin Xu, Principal Investigator at the BRITE Research Institute and Associate Professor of Pharmaceutical Sciences at North Carolina Central University (NCCU)
"*Translational Neuroscience: Early Alzheimer's Disease Diagnosis and Aging-Related Inhibitor Discovery*"

12:00-12:30 Lunch Available for All Registrants and Guest Speakers

12:30-3:00 Faculty Presentations
12:30 – 1:15 Leon Coleman, Jr, MD/PhD, UNC-Chapel Hill
"*The Role of Microglia and Extracellular Vesicles in Behavioral and Neurobiological Pathology in Alcohol Use Disorder*"
1:20 – 2:05 Richard Lamb, PhD, University of Georgia
"*Prediction of Student and Client Cognitive Status Using Neurological and Machine Learning Technologies*"
2:10 – 2:55 Tuan Tran, PhD, East Carolina University
"*The Effects of Small Molecule Modulators in the Triple-Transgenic Mouse Model of Alzheimer's Disease Using Eyeblink Classical Conditioning*"

3:00-4:00 Poster Session

4:00-4:15 Closing Remarks and Awards: Tuan Tran, PhD, ECCSfN Interim President



Bin Xu, PhD is a Principal Investigator at the BRITE Research Institute and Associate Professor of Pharmaceutical Sciences at North Carolina Central University (NCCU). He is also faculty Co-Director of the Neurobehavioral Core at NCCU and an affiliated faculty at the Duke-UNC Alzheimer's Disease Research Center. After earning his PhD in Biomedical Sciences at Case Western Reserve University School of Medicine, Dr. Xu did a postdoctoral research fellowship at Fred Hutchinson Cancer Research Center. Prior to joining BRITE of NCCU, he was a faculty of Biochemistry and Neuroscience at Virginia Tech. His research group focuses on translational aging research, in particular, Alzheimer's disease biomarker discovery for early diagnosis, and drug discovery for Alzheimer's and diabetes-induced neurodegeneration.

Leon G. Coleman, Jr, MD, PhD is an Assistant Professor in the Department of Pharmacology at the University of North Carolina at Chapel Hill. After completing his graduate training, he completed two years of general surgery residency followed by a postdoctoral fellowship where he studied the role of central and peripheral immune signaling in pathology associated with alcohol use disorder and severe burn injury. His research goal is to identify novel therapeutic targets for immune-related conditions such as alcohol use disorder, Alzheimer's disease, cancer, and trauma.

Richard Lamb, PhD is an Associate Professor of the Department of Physiology and Pharmacology and the Department of Clinical and Administrative Pharmacy in the College of Veterinary Medicine and College of Pharmacy, respectively. He is currently the director of the Neurocognition Science Laboratory at the University of Georgia. He earned his PhD from George Mason University, College of Education and Human Development in 2013 in Science Education and Measurement. His research focuses on the identification of cognitive markers of learning, increasing efficacy and performance of information processing, and cognition using novel technologies such as machine learning and artificial intelligence in digital environments.

Tuan Tran, PhD is Associate Professor of Neuroscience and Psychology and is Director of Undergraduate Research at East Carolina University. He earned his PhD from the University of South Carolina, Columbia. After earning his PhD, Dr. Tran was an NIAAA postdoctoral scholar in the Developmental Psychobiology Program at IUPUI. Dr. Tran's current research interests involve examining rodent models of neurodegenerative disorders. This involves examining behavioral and cognitive deficits in triple-transgenic (3xTg-AD) mice that bear the PS1-M146V, APP-Swe, and tauP301L mutations – mutations that lead to hallmark pathologies in Alzheimer's disease (AD). Eyeblink classical conditioning and the spatial version of the Morris maze task are used to assess cognitive dysfunction in these mice. His goal is to test the feasibility of small molecule modulators that have gained much interest as of late in minimizing the impact of AD pathology and cognitive disabilities in general.